ICI-118,551

ICI-118,551 is a selective β2 adrenergic receptor antagonist. It is used in medical research to understand the function and action of the β2 receptor, due to its specificity and selectivity for this subtype. ICI-118,551 has been found to increase the contractility of the heart in studies on animals, suggesting potential therapeutic uses in heart failure. However, it is not currently used clinically for this purpose.

Pharmacology

ICI-118,551 is a selective antagonist for the β2 adrenergic receptor. This means it binds to these receptors and blocks their activation by agonists. It does not have significant activity at other adrenergic receptors, such as the β1 or β3 receptors.

Uses in Research

Due to its selectivity for the β2 receptor, ICI-118,551 is often used in research to understand the function of this receptor subtype. It has been used in studies investigating the role of the β2 receptor in the heart, lungs, and other tissues.

Potential Therapeutic Uses

In animal studies, ICI-118,551 has been found to increase the contractility of the heart. This suggests it could potentially be used to treat heart failure. However, further research is needed to confirm this potential use and to understand the safety and efficacy of ICI-118,551 in humans.

See Also

• Beta blocker
• Beta-2 adrenergic receptor
• Heart failure

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia